Analysts Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $15.00

Shares of Nkarta, Inc. (NASDAQ:NKTX) have received an average rating of “Buy” from the seven research firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.00.

A number of brokerages have weighed in on NKTX. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. HC Wainwright decreased their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Needham & Company LLC lowered their price target on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Raymond James upgraded shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research note on Wednesday, August 14th. Finally, Mizuho lowered their target price on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st.

Institutional Trading of Nkarta

Several hedge funds and other institutional investors have recently bought and sold shares of NKTX. Franklin Resources Inc. bought a new stake in shares of Nkarta in the 3rd quarter worth approximately $151,000. Barclays PLC lifted its position in Nkarta by 161.4% in the third quarter. Barclays PLC now owns 232,566 shares of the company’s stock worth $1,051,000 after purchasing an additional 143,608 shares during the period. Geode Capital Management LLC lifted its position in Nkarta by 3.0% in the third quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock worth $5,294,000 after purchasing an additional 33,927 shares during the period. XTX Topco Ltd acquired a new stake in Nkarta during the third quarter worth $223,000. Finally, Wellington Management Group LLP increased its holdings in Nkarta by 24.8% in the 3rd quarter. Wellington Management Group LLP now owns 216,341 shares of the company’s stock valued at $978,000 after buying an additional 43,035 shares during the period. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Down 4.0 %

NKTX stock opened at $2.87 on Thursday. The firm has a market cap of $202.54 million, a PE ratio of -1.53 and a beta of 0.86. Nkarta has a 1 year low of $2.38 and a 1 year high of $16.24. The company has a fifty day simple moving average of $3.54 and a 200 day simple moving average of $5.11.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.